Pharmacokinetics and immunogenicity of eftozanermin alfa in subjects with previously-treated solid tumors or hematologic malignancies: results from a phase 1 first-in-human study.
Carla BiesdorfXiaowen GuanSatya R SiddaniDavid HoffmanNils BoehmBruno C MedeirosToshihiko DoiMaja de JongeDrew RascoRajeev M MenonAkshanth R PolepallyPublished in: Cancer chemotherapy and pharmacology (2023)
NCT03082209.